A confirmed dysregulation of the GBA/GBAP1/miR-22-3p circuit in PD patients would suggest possible novel therapeutic strategies, based either on the direct control of the expression of the miRNA/pseudogene, or on the modulation of the NMD pathway aimed at up-regulating GBAP1 levels48. Here, GBA1 is linked to Parkinson disease.